PTO/SB/21 (09-04)



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/774,176
Filing Date	February 6, 2004
First Named Inventor	Carroll, Miles W.
Art Unit	1644
Examiner Name	Marianne NMN Dibrino
Attorney Docket Number	021911-000510US

145 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final **Proprietary Information Provisional Application** Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please identify Extension of Time Request **Terminal Disclaimer** below): Form PTO/SB/08A,B, 12 references, return **Express Abandonment Request** Request for Refund postcard Information Disclosure Statement CD, Number of CD(s) Landscape Table on CD The Commissioner is authorized to charge any additional fees to Deposit Remarks Certified Copy of Priority Account 20-1430. Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Townsend and Townsend and Crew LLP Signature 221 Printed name Kawai Lau Date Reg. No. December 12, 2005 44,461

I hereby certify that this co envelope addressed to: N below.	orrespondence is being dep Mail Stop Amendment, Cou						
Signature		Timothe	S. Parley				
Typed or printed name	Timothy S. Parker	J		Date	Decemb	per 12, 2005	

December 12, 2005

CERTIFICATE OF TRANSMISSION/MAILING

Typed or printed name

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 021911-000510US Client Reference No.: OBM30Div

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TOWNSEND and TOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Miles W. Carroll, et al.

Application No.: 10/774,176

Filed: February 6, 2004

For: POLYPEPTIDE

Examiner: Marianne NMN Dibrino

Art Unit: 1644

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Page 2

Applicant believes that <u>no fee is required</u> for submission of this statement, because this submission is prior to the issuance of a first Office Action on the merits.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Kawai Lau Reg. No. 44,461

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 858-350-6100 Fax: 415-576-0300

KL:tsp 60655067

DEC: 1 4 7005 W

tute for form 1449A/PTO Complete if Known **Application Number** 10/774,176 **INFORMATION DISCLOSURE** Filing Date February 6, 2004 STATEMENT BY APPLICANT First Named Inventor Carroll, Miles W. 1644 Art Unit (use as many sheets as necessary) Marianne NMN Dibrino **Examiner Name** Sheet of 2 Attorney Docket Number 021911-000510US

	U.S. PATENT DOCUMENTS+							
Examiner Initials*	Cite No.1	Document Number Number Kind Code ² (<i>il known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	AA	US-						
	AB	US-						
	AC	US-						
	AD	US						
	AE	.US-						
,	AF	US-						
	AG	US-		·				
	AH	US-						
	Al	US-						
	AJ	US-						
	AK	US-	·					
	AL	US-						
	AM	US-						
	AN	US-						
	AO	US-						
	AP	US-						
	AQ	US-						
•	AR	US-						
	AS	US-						
	AT	US-						

			FO	REIGN PA	TENT DOCUME	ENTS		
Examiner Initials*	Cite No. ¹	For	eign Patent Docume Number ⁴ Kind	nt d Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AU	PCT	WO97/19183	A2	05/29/1997	Glaxo Group Limited		
	AV		<u>-</u>					
	AW							
	AX							
	AY			,				
	AZ							
	BA							
	BB					•		

	Examiner Signature		Date Considered	
--	-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.

60655067 v1

Substitute for form 1449B/PTO				Complete if Known		
INICO	Draktie	N DIO	OL OCUDE	Application Number	10/774,176	
INFORMATION DISCLOSURE				Filing Date	February 6, 2004	
STATEMENT BY APPLICANT		First Named Inventor	Carroll, Miles W.			
				Art Unit	1644	
(4	use as many	/ sheets as	necessary)	Examiner Name	Marianne NMN Dibrino	
Sheet	2	of	2	Attorney Docket Number	021911-000510US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	вс	CORREALE, Pierpaolo, et al. "Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate- Specific Antigen (PSA) Employing a PSA Oligoepitope Peptide", <i>The Journal of Immunology</i> (1998) 161:3186-3194	
	BD	HODGE, James W., et al. "A Recombinant Vaccinia Virus Expressing Human Prostate-Specific Antigen (PSA): Safety and Immunogenicity in a Non-Human Primate", Int. J. Cancer (1995) 63:213-237	
	BE	HOLE, N., et al. "A 72 kD trophoblast glycoprotein defined by a monoclonal antibody", <i>Br. J. Cancer</i> (1998) 57:239-246	
	BF	IRVINE, Kari R., et al. "Synthetic Olignoucleotide Expressed by a Recombinant Vaccinia Virus Elicits Therapeutic CTL", <i>The Journal of Immunology</i> (1995) <i>154:</i> 4651-4657	
	BG	JACKSON, Ronald J., et al. "Infertility in Mice Induced by a Recombinant Ectromelia Virus Expressing Mouse Zona, Pellucida Glycoprotein 3", <i>Biology of Reproduction</i> (1998) 58:152-159	
	вн	KASS, Erik, et al. "Induction of Protective Host Immunity to Carcinoembryonic Antigen (CEA), a Self-Antigen in CEA Transgenic Mice, by Immunizing with a Recombinant Vaccinia-CEA Virus", Cancer Research (1999) 59:676-683	
	ВІ	ROSATO, Antonio, et al. "CTL Response and Protection Against P815 Tumor Challenge in Mice Immunized with DNA Expressing the Tumor-Specific Antigen P815A", <i>Human Gene Therapy</i> (1997) 8:1451-1458	
	BJ	SANDA, Martin G., et al. "Recombinant Vaccinia-PSA (Prostvac) Can Induce a Prostate-Specific Immune Response in Androgen-Modulated Human Prostate Cancer", <i>Urology</i> (1999) 53:260-266	
**	BK	SOUTHALL, P.J., et al. "Immunohistological distribution of 5T4 antigen in normal and malignant tissues", Br. J. Cancer (1990) 61:89-95	
	BL	TSANG, Kwong Y., et al. "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine", <i>J. Natl. Cancer Inst.</i> (1995) 87(13):982-990	
	ВМ	WANG, Rong-Fu "Tumor Antigens Discovery: Perspectives for Cancer Therapy", <i>Molecular Medicine</i> (1997) 3(11):716-731	

Examiner	Date)
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.